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Abstract
Background: Diabetic patients show an increased prevalence of non-dipping arterial pressure pattern, target organ
damage and elevated arterial stiffness. These alterations are associated with increased cardiovascular risk.
The objectives of this study are the following: to evaluate the prognostic value of central arterial pressure and
pulse wave velocity in relation to the incidence and outcome of target organ damage and the appearance of car-
diovascular episodes (cardiovascular mortality, myocardial infarction, chest pain and stroke) in patients with type 2
diabetes mellitus or metabolic syndrome.
Methods/Design: Design: This is an observational prospective study with 5 years duration, of which the first year
corresponds to patient inclusion and initial evaluation, and the remaining four years to follow-up.
Setting: The study will be carried out in the urban primary care setting.
Study population: Consecutive sampling will be used to include patients diagnosed with type 2 diabetes
between 20-80 years of age. A total of 110 patients meeting all the inclusion criteria and none of the exclusion cri-
teria will be included.
Measurements: Patient age and sex, family and personal history of cardiovascular disease, and cardiovascular risk
factors. Height, weight, heart rate and abdominal circumference. Laboratory tests: hemoglobin, lipid profile, creati-
nine, microalbuminuria, glomerular filtration rate, blood glucose, glycosylated hemoglobin, blood insulin, fibrinogen
and high sensitivity C-reactive protein. Clinical and 24-hour ambulatory (home) blood pressure monitoring and self-
measured blood pressure. Common carotid artery ultrasound for the determination of mean carotid intima-media
thickness. Electrocardiogram for assessing left ventricular hypertrophy. Ankle-brachial index. Retinal vascular study
based on funduscopy with non-mydriatic retinography and evaluation of pulse wave morphology and pulse wave
velocity using the SphygmoCor system. The medication used for diabetes, arterial hypertension and hyperlipidemia
will be registered, together with antiplatelet drugs.
Discussion: The results of this study will help to know and quantify the prognostic value of central arterial
pressure and pulse wave velocity in relation to the evolution of the subclinical target organ damage markers and
the possible incidence of cardiovascular events in patients with type 2 diabetes mellitus.
Trial Registration: ClinicalTrials.gov Identifier: NCT01065155
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Background
The estimated prevalence of type 2 diabetes mellitus
(DM2) in the industrialized world is 6-8% [1]. The pre-
valence of the disease is expected to increase in the
coming years as a result of the increase in life expec-
tancy in developed countries, and as a consequence of
changes in life style in the developing world. It has been
estimated that the number of diabetics will double over
the next 25 years. As a result, by the year 2030, Spain
can be expected to have over three million diabetic
patients [1,2]. Cardiovascular diseases are the main
causes of mortality among diabetic patients [3]. The
incidence of coronary mortality in DM2 patients is four
times greater than in the general population [4,5]. On
the other hand, the prevalence of arterial hypertension
(AHT) in DM2 is practically twice as high as in the
non-diabetic population. Thus, 50-60% of all DM2
patients are hypertensive, and this percentage increases
with age and the presence of nephropathy [6-8]. AHT in
the diabetic patient is usually systolic [9-12], its control
poses greater difficulties [13,14], and the nocturnal dip
in pressure is smaller [15]. Moreover, the concomitant
presence of both conditions (AHT and DM2) increases
cardiovascular morbidity-mortality - with an increased
incidence of coronary, cerebrovascular, and peripheral
vascular disease, renal failure, heart failure and diabetic
retinopathy, and a greater risk of death due to cardio-
vascular disease [16].
Clinical blood pressure (CBP) measurement remains
the standard of reference, and has been a key element in
predicting cardiovascular disease, but there is increasing
evidence that home blood pressure (HBP) measurement
by the patient, and particularly ambulatory blood pres-
sure monitoring (ABPM), shows a stronger correlation
to target organ damage and cardiovascular events
[17-20]. The prognostic value of nocturnal blood pres-
sure (BP), and particularly of the nocturnal decrease or
dip in systolic blood pressure (SBP), seems to be greater
than that of diurnal BP. Individuals with a lower noctur-
nal fall in BP have a greater prevalence of target organ
damage and a less favorable outcome [21,22].
The presence of target organ damage increases the
risk of clinical cardiovascular complications in DM2. In
this context, left ventricular hypertrophy (LVH),
assessed according to electrocardiographic criteria,
increases the risk of coronary complications and stroke
[23]. Silent worsening of renal function, reflected by
increased creatinine levels, a drop in glomerular filtra-
tion rate (GFR), or an increase in protein excretion in
urine, increase the risk of cardiovascular diseases
[24,25]. Pathological ankle-brachial index (ABI) values
show very good correlation to the development of cor-
onary complications, the incidence of stroke, and cardio-
vascular mortality [26]. In addition, a number of
prospective studies have shown carotid artery intima-
media thickness (IMT) to be an independent risk factor
for both coronary disease and stroke [27]. An increased
IMT and/or the detection of atheroma plaques are asso-
ciated with an up to four-fold increase in the relative
risk of clinical complications of arteriosclerosis [28].
On the other hand, the evaluation of major artery
stiffness is gaining importance as an indicator, since it is
one of the main determining factors of the general con-
dition of blood circulation [29,30]. Arterial stiffness is
determined via two systems: pulse wave velocity (PWV)
(time from arrival of the pulse wave to the carotid artery
and femoral artery) and applanation radial tonometric
pulse wave analysis for calculating aortic pressure, as
well as the relationships between the latter and the per-
ipheral pressure values [31-33]. Increased arterial stiff-
ness or diminished arterial distensibility determined by
pulse pressure implies increased cardiovascular risk. On
the other hand, there is evidence that diabetes predis-
poses to premature vascular aging.
Considering the need in diabetic patients to better
establish the prognostic value of central arterial pressure
and pulse wave velocity in relation to the evolution of
the target organ damage markers (left ventricle growth
indicators, renal damage markers (microalbuminuria
and diminished glomerular filtration), retinal damage
and vascular markers (IMT of the carotid artery and
ABI)) and the possible incidence of cardiovascular
events in DM2 patients, an observational prospective
study involving annual follow-up over at least four years
is contemplated.
The following objectives have been established
To evaluate the prognostic value of central arterial pres-
sure and pulse wave velocity in relation to the incidence
and outcome of renal (microalbuminuria, diminished glo-
merular filtration and the appearance of terminal renal
failure), cardiac (LVH) and vascular damage (IMT and
ABI), retinal vascular impairment, and the appearance of
cardiovascular episodes (cardiovascular mortality,
ischemic heart disease and stroke) in patients with DM2.
Methods/Design
Study design
An observational prospective study with a duration of 5
years, of which the first year corresponds to patient
inclusion, and the remaining four years to follow-up.
A minimum of 5 visits are contemplated, comprising a
baseline visit at the time of patient inclusion in the
study, and annual follow-up visits.
The study was approved by an independent ethics
committee from the University Hospital of Salamanca
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(Spain), and all participants signed an informed consent
document.
Setting
The study will be carried out in the rural primary care
setting, in the research unit of La Alamedilla primary
care center, to which the general practitioners from two
primary care centers serving a population of 46,000
inhabitants send patients for the evaluation of possible
target organ damage and vascular risk.
Study subjects
Consecutive inclusion will be made of the patients
referred to the research unit and who meet the corre-
sponding inclusion criteria, i.e., patients diagnosed with
DM2 and aged 20-80 years, with none of the following
exclusion criteria: patients unable to comply with the
protocol requirements (psychological and/or cognitive
disorders, failure to cooperate, educational limitations
and problems for understanding written language, fail-
ure to sign the informed consent document), patients
participating or who will participate in a clinical trial
during the study, and patients with serious comorbid-
ities representing a threat to life over the subsequent 12
months.
The sample size has been calculated to determine the
time the patients take in suffering an event - the latter
being interpreted as morbidity-mortality or the appear-
ance of new target organ damage. To this effect, two
groups will be considered, classified according to the
median central arterial pressure value. The study accepts
an alpha risk of 0.05 and a beta risk of 0.30 in two-sided
contrasting for the detection of a minimum difference in
relative risk between the two groups of ≥ 2.5 points, and
considering an events rate within the high central arter-
ial pressure group (values above the median) of 35% at
the end of the study period. A total of 52 patients are
required in each group, estimating a loss to follow-up of
10%. A final total of 110 patients therefore will be
included.
Measurements
Sociodemographic variables and cardiovascular risk factors
Patient age, sex, race, educational level and occupa-
tional status. Hypertension, dyslipidemia, alcohol
consumption, smoking, physical activity and a history
of premature cardiovascular disease (before 55 years of
age in males and before 65 in females) in first-degree
relatives.
Cardiovascular diseases
Coronary events: Myocardial infarction, unstable angina,
stable angina, coronary revascularization. Cerebrovascu-
lar events: Ischemic stroke, intracranial hemorrhage,
transient brain ischemia. Hospital admissions due to
heart failure. Symptomatic peripheral arterial disease:
Claudication over a distance of less than 100 m, resting
pain, amputation. Heart failure. Atrial fibrillation.
Treatment variables
Treatment for diabetes. Antihypertensive treatment.
Lipid-lowering treatment. Antiplatelet treatment.
Anthropometric measurements
Body weight is to be determined on two occasions using
a homologated electronic scale (Seca 770) following due
calibration (precision ± 0.1 kg), with the patient wearing
light clothing and no shoes. These readings will be
rounded to 100 g. Height in turn will be measured with
a portable system (Seca 222), recording the average of
two readings, and with the patient shoeless in the stand-
ing position. The values will be rounded to the closest
centimeter. Body mass index (BMI)(kg/m2) will be cal-
culated. Waist circumference will be measured using a
flexible graduated measuring tape with the patient in
the standing position without clothing. The upper bor-
der of the iliac crests are located, and the tape is
wrapped around above this point, parallel to the floor,
ensuring that it is adjusted without compressing the
skin. The reading is taken at the end of a normal breath
according to the recommendations of the 2007 SEEDO
Conference [34].
Laboratory parameters
Lipids, creatinine, glucose, high-sensitivity C-reactive
protein (CRP), fibrinogen and glycosylated hemoglobin
(HbA1c) in blood and microalbuminuria. The para-
meters will be measured on a blind basis in the refer-
ence laboratory after patient fasting for at least 8 hours.
Office or clinical blood pressure
Office blood pressure measurement involves three mea-
surements of systolic (SBP) and diastolic blood pressure
(DBP), using the average of the last two, with a validated
OMRON model M7 sphygmomanometer (Omron
Health Care, Kyoto, Japan), by following the recommen-
dations of the European Society of Hypertension [35].
Pulse pressure (PP) will be estimated with the mean
values of the second and third measurements.
Home blood pressure (HBP)
This parameter will be measured using an OMROM
model M7 sphygmomanometer (Omron Health Care,
Kyoto, Japan). Three measurements will be made in the
morning (between 6:00 and 9:00 a.m.), and three in the
afternoon/evening (between 18:00 and 21:00 p.m.), over
a period of 7 days, with a minimum interval of one min-
ute between measurements, and excluding the first mea-
surement in each case and the values corresponding to
the first day of measurement [36]. The investigator will
instruct the patients on how to perform the blood pres-
sure recordings at home. Written instructions will be
provided, as well as a self-registry sheet, to ensure cor-
rect pressure monitoring.
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Ambulatory blood pressure monitoring (ABPM)
The ABPM was performed on a day of standard activity,
with an adequate cuff for the size of the patient’s arm. A
control system, SpaceLabs 90207 model (Spacelabs
Healthcare, Issaquah, Washington, USA), validated
according to the protocol of the British Hypertension
Society, was used [37]. The records in which the percen-
tage of valid readings was ≥66% of the total and with
valid readings at all times were considered to be valid.
Furthermore, for the records to be evaluable, at least 14
measurements were required during the daytime period,
or at least seven during the nightime or rest period. The
monitor was scheduled for obtaining blood pressure mea-
surements every 20 min during the daytime period and
every 30 min during the rest period. The average and dis-
persión estimators of SBP and DBP were calculated dur-
ing the 24-h, daytime and nightime periods, defined
based on the diary reported by the patient. The patient
completes a form specifying bedtime and wake-up time.
Assessment of carotid intima-media thickness
Carotid ultrasonography to assess IMT was performed by
two investigators specifically trained for this before start-
ing the study. A Sonosite Micromax ultrasound (Sonosite
Inc., Bothell, Washington, USA) device paired with a
5-10 Mhz multifrequency high-resolution linear trans-
ducer with Sonocal software was used for performing
automatic measurements of IMT for optimising reprodu-
cibility. Measurements were made of the primitive carotid
after the examination of a longitudinal section of 10 mm
at a distance of 1 cm from the bifurcation, performing
measurements in the anterior or proximal wall, and in
the posterior or distal wall in the lateral, anterior and
posterior projections, following an axis perpendicular to
the artery to discriminate two lines, one for the intima-
blood interface and the other to the media-adventitious
interface. A total of 6 measurements were obtained of
the right carotid and other 6 of the left carotid, using
average values (average IMT) and maximum values (max-
imum IMT) calculated by the software automatically. The
measurements were obtained with the subject lying
down, with the head extended and slightly turned oppo-
site to the carotid examined, following the recommenda-
tions of the Manheim Carotid Intima-Media Thickness
Consensus [38]. Finally, IMT image is frozen in teledias-
tole by means of electrocardiogram triggering to avoid a
confounding effect of pulsatile deformation of wall thick-
ness and transferred to a computer. The average IMT
was considered to be abnormal if it was above 0.9 mm,
or if there were atherosclerotic plaques with a diameter
over 1.5 mm, or a focal increase of 0.5 mm, or 50% of
the adjacent IMT [16].
Evaluation of peripheral artery involvement
This was evaluated using the ankle-brachial index (ABI),
performed in the morning without having consumed
coffee or tobacco for at least 8 hours prior to measuring
and an ambient temperature of 22-24°C. With the feet
uncovered, in a supine decubitus position after 20 min-
utes of rest, the pressure in the lower extremities was
measured using a portable Doppler system Minidop Es-
100Vx (Hadeco, Inc. Arima, Miyamae-ku, Kawasaki,
Japan) applying the probe at the anterior or posterior
tibial artery at an angle of approximately 60° to the
direction of blood flow. The transducer’s cuff was
quickly inflated in each ankle about 30 mmHg above
the systolic pressure and the pressure was allowed to
descend (by about 2 mmHg per second) until the first
sound corresponding to the systolic pressure was heard.
The blood pressure was also measured in both arms
(measured twice at 3-5 minute intervals). The ABI was
calculated separately for each foot by dividing the higher
of the two systolic pressures in the ankle by the highest
of the two systolic pressures in the arm [39]. It is con-
sidered subclinical organ damage if it is lower than 0.9
[16].
Cardiac assessment
The electrocardiographic examination was performed with
a General Electric MAC 3.500 ECG System (Niskayuna,
New York, USA), that measures automatically the voltage
and duration of waves and estimates the criteria of the
Cornell voltage-duration product (Cornell VDP) [40] to
assess the LVH by the following equation: Men ((RaVL +
SV3) * QRS) and women ((RaVL + SV3) * QRS + 6). LVH
is defined as the voltage-duration product > 2,440 mm/ms
(16). We will estimate left ventricular mass index (LVMI)
by Novacode equation [41].
Renal assessment
The kidney damage was assessed by measuring creati-
nine plasma concentration, the glomerular filtration rate
was estimated by CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) [42] and the MDRD-IDMS
(Modification of Diet in Renal Disease-Isotopic Dilution
Mass Spectrometry) [43] equation and proteinuria were
assessed by the albumin/creatinine ratio following the
2007 European Society of Hypertension/European
Society of Cardiology Guidelines criteria [16]. Subclini-
cal organ damage was defined as plasma creatinine
between 1.3 - 1.5 mg/dl in men and 1.2 - 1.4 mg/dl in
women, glomerular filtration rate below 60 ml/min or
albumin/creatinine ratio > 22 mg/gr in men and 31 mg/
gr in women. Renal disease was defined as plasma crea-
tinine of 1.5 mg/dl or higher in men and 1.4 mg/l in
women or albumin/creatinine ratio > 300 mg/24 h.
Evaluation of retinal involvement
Retinography was performed with a Topcon TRC NW
200 non-mydriatic retinal camera (Topcon Europe B.C.
Capelle a/d IJssel The Netherlands), obtaining images
centered on the papilla. Once the images were captured,
two independent observers classified them according to
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the Keith-Wagener classification for hypertensive retino-
pathy [44], with a third reading being performed in
cases where there were discrepancies. Grades III or IV
(hemorrhages or exudates, papillary edema) are consid-
ered to be associated with cardiovascular disease [16].
Evaluation of pulse wave velocity and central blood
pressure
The pulse wave velocity (PWV) was calculated using the
SphygmoCor System (Vx Pulse Wave Velocity), (AtCor
Medical Pty Ltd Head Office, West Ryde, Australia)
with the patient in the supine decubitus position. The
carotid and femoral pulse wave was analyzed, estimating
the delay in the electrocardiograma (ECG) wave and cal-
culating the PWV. The space measurements were taken
with a measuring tape from the suprasternal notch to
the carotid and femoral arteries at the sensor location.
A measurement of greater than 12 m/s is considered
subclinical organ damage [16].
Using the SphygmoCor system (Px Pulse Wave Analy-
sis)(Atcor Medical, Australia), with the patient in the sit-
ting position and resting the arm on a rigid surface,
pulse wave analysis will be made with a sensor in the
radial artery - using mathematical transformation to
estimate the aortic pulse wave. From the aortic wave
morphology, central (aortic) arterial pressure will be
estimated, along with central ventricular load, diastolic
perfusion pressure, the subendocardial viability index,
the pressure increment, central pulse pressure and the
augmentation index (PWA), defined as the percentage
increase in central pulse pressure: AIx = pressure
increase/pulse pressure * 100 [33].
All explorations will be carried out on a yearly basis,
and due registry will be made of any changes in the
sociodemographic variables or cardiovascular risk fac-
tors, and of the appearance of events.
Organization of data collection
The patients referred to the research unit of La Alame-
dilla primary care center will be interviewed by a con-
tracted nurse specifically trained for the project. A
history will be compiled and a basic exploration will be
carried out. A 24-hour ambulatory blood pressure moni-
toring (ABPM) device will be fitted, and the patients will
receive an OMRON M7 sphygmomanometer for self-
measurement of blood pressure at home. Vascular
exploration will be made (pulse analysis with the Sphyg-
moCor system, ABI and ECG), and an appointment will
be made for blood sampling. Posteriorly, carotid artery
ultrasound will be performed by two specifically trained
members of the research team. Data input will be made
using the Teleform system (Autonomy Cardiff Vista,
California, USA), with a questionnaire previously
designed for the project, and exporting the data to the
SPSS version 15.0 statistical package (SPSS Inc., Chi-
cago, Illinois, USA) for posterior analysis.
Statistics analysis
A first descriptive analysis will be made of the sociode-
mographic and clinical characteristics of the study
groups. The data will be presented with the mean and
95% confidence interval in the case of quantitative vari-
ables, and as frequency distributions for qualitative vari-
ables. The Pearson chi-squared test will be used to
analyze associations between qualitative variables. The
Student t-test for independent samples will be used to
compare the means for the two arterial pressure groups.
In turn, the analysis of repeated measures will be based
on the McNemar test for qualitative data and the Student
t-test for paired data in application to quantitative data.
Survival will be analyzed with the Kaplan-Meier and
actuarial methods on each visit and at the end of fol-
low-up. The log-rank test will be used for comparing
survival in the two groups. Lastly, a Cox regression
model will be developed to estimate the event risk
between the groups, adjusting for the possible con-
founding variables analyzed in the study.
Hypothesis contrasting will establish an alpha risk fac-
tor of 0.05 as the limit of statistical significance. The
SPSS/PC+ version 15.0 statistical package will be used
(SPSS Inc., Chicago, Illinois, USA).
Quality control
Different processes will be carried out to guarantee
study data quality and thus maximize the validity and
reliability of the measurements of the results. To this
effect, field work operative manuals have been devel-
oped, specifying the correct technique for performing
each of the tests. Educative leaflets have also been devel-
oped to ensure that the patients correctly perform pres-
sure measurement in the home - all these measures
confirming the correct practical application of each
technique. Meetings will be held on a weekly basis with
the principal investigator of the study in order to ana-
lyze the entire process, and an annual report on the
course of the study will be prepared.
Ethical and legal issues
In order to guarantee data confidentiality, all the elec-
tronic and paper copies of the protocol, signed informed
consent documents and results of the tests made in
each of the patients will be kept locked in a safe place,
and only the study investigators will have access to the
data on the subjects who agree to participate in the
study.
The study has been approved by the ethics committee
and complies with Spanish data protection law 15/1999
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and its recently developed specifications (Royal Decree
(RD) 1720/2007). Knowledge and agreement to coop-
erate has been established with the implicated services,
signed by the legal representative of the center.
Discussion
The results of this study will be of great scientific rele-
vance, since they will allow us to quantify the degree to
which central arterial pressure and pulse wave velocity
are related to the different target organ lesions (carotid
IMT, peripheral arterial disease, kidney, retina and
heart), and to analyze their course over time. To our
knowledge, this is the first study to assess target organ
damage in diabetic patients and its relationship to cen-
tral arterial pressure and pulse wave velocity over a fol-
low-up period of at least four years.
Pulse wave velocity is the gold standard for assessing
the stiffness of the large arteries, and is an important
predictor of cardiovascular events [45]. A recent review
[46] has shown it to be correlated to patient age and
arterial pressure, though its association to diabetes is
not so clear. Discrepancies have been observed among
different studies, and the recorded associations are weak
[45]. Likewise, it is not certain that the different instru-
ments used to assess arterial stiffness are equivalent. In
this sense, a study in diabetic patients has concluded
that pulse pressure and pulse wave velocity increase in
diabetic individuals, though this is not associated to the
augmentation index, and such parameters may not be
reliable as a measure of arterial stiffness in diabetics
[47]. In this same line, another study comparing differ-
ent procedures for assessing arterial stiffness in diabetic
subjects has concluded that further research is needed
to clarify their usefulness in diabetic patients [48].
As regards the relationship between these arterial stiff-
ness measures and target organ lesions and their course
over time in diabetic individuals, the existing evidence is
scarce and inconclusive. With the present study we
hope to contribute evidence to clarify some of these
issues.
Study limitations
The main limitation of this study is its small sample size
for assessing end events. However, this is remedied by
the fact that the analysis will be made with the data of a
multicenter study in which 800 patients will be included.
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